Shattuck Labs, Inc. Increase (Decrease) in Accrued Liabilities
Shattuck Labs, Inc. (STTK) reported Increase (Decrease) in Accrued Liabilities of -$1.16 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-11
- Shattuck Labs, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $793.00K.
- Shattuck Labs, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$1.96M.
- Shattuck Labs, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $882.00K.
- Shattuck Labs, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$687.00K.
- Shattuck Labs, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$1.44M.
- Shattuck Labs, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$3.37M.
- Shattuck Labs, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was -$8.29M, a 378.76% decline from fiscal 2022.
- Shattuck Labs, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $2.98M, a 57.03% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $793.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.16M 10-Q · filed 2026-08-11 | -$280.00K derived: sum of 3 quarters · filed 2026-08-11 | -$967.00K derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2026-03-31 | -$1.96M 10-Q · filed 2026-05-07 | -$1.07M derived: sum of 2 quarters · filed 2026-05-07 | -$1.76M derived: sum of 3 quarters · filed 2026-05-07 | -$2.68M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-12-31 | $882.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $195.00K derived: sum of 2 quarters · filed 2026-03-05 | -$726.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.44M 10-K · filed 2026-03-05 | ||
| 2025-09-30 | -$687.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.61M derived: sum of 2 quarters · filed 2026-08-11 | -$2.32M 10-Q · filed 2025-11-06 | -$5.30M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-06-30 | -$921.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.64M 10-Q · filed 2026-08-11 | -$4.61M derived: sum of 3 quarters · filed 2026-08-11 | -$4.69M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-31 | -$716.00K 10-Q · filed 2026-05-07 | -$3.69M derived: sum of 2 quarters · filed 2026-05-07 | -$3.77M derived: sum of 3 quarters · filed 2026-05-07 | -$2.13M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | -$2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$3.05M derived: sum of 2 quarters · filed 2026-03-05 | -$1.41M derived: sum of 3 quarters · filed 2026-03-05 | -$3.37M 10-K · filed 2026-03-05 | ||
| 2024-09-30 | -$76.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.56M derived: sum of 2 quarters · filed 2025-11-06 | -$392.00K 10-Q · filed 2025-11-06 | -$2.43M derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$316.00K 10-Q · filed 2025-08-14 | -$2.36M derived: sum of 3 quarters · filed 2025-08-14 | -$1.05M derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | -$1.95M 10-Q · filed 2025-05-01 | -$4.00M derived: sum of 2 quarters · filed 2025-05-01 | -$2.69M derived: sum of 3 quarters · filed 2025-05-01 | -$2.89M derived: sum of 4 quarters · filed 2025-05-01 | ||
| 2023-12-31 | -$2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$738.00K derived: sum of 2 quarters · filed 2025-03-27 | -$937.00K derived: sum of 3 quarters · filed 2025-03-27 | -$8.29M 10-K · filed 2025-03-27 | -$8.64M 10-K · filed 2024-02-29 | |
| 2023-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.10M derived: sum of 2 quarters · filed 2024-11-14 | -$6.25M 10-Q · filed 2024-11-14 | -$6.31M 10-Q · filed 2023-11-09 | -$4.34M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$199.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$7.55M 10-Q · filed 2024-08-01 | -$5.65M derived: sum of 3 quarters · filed 2024-08-01 | -$8.12M derived: sum of 4 quarters · filed 2024-08-01 | ||
| 2023-03-31 | -$7.36M 10-Q · filed 2024-05-02 | -$5.45M derived: sum of 2 quarters · filed 2024-05-02 | -$7.92M derived: sum of 3 quarters · filed 2024-05-02 | -$3.78M derived: sum of 4 quarters · filed 2024-05-02 | ||
| 2022-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$564.00K derived: sum of 2 quarters · filed 2024-02-29 | $3.58M derived: sum of 3 quarters · filed 2024-02-29 | $2.98M 10-K · filed 2024-02-29 | ||
| 2022-09-30 | -$2.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.67M derived: sum of 2 quarters · filed 2023-11-09 | $1.07M 10-Q · filed 2023-11-09 | $1.56M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $4.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $3.54M 10-Q · filed 2023-08-10 | $4.03M derived: sum of 3 quarters · filed 2023-08-10 | $6.49M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | -$601.00K 10-Q · filed 2023-05-09 | -$108.00K derived: sum of 2 quarters · filed 2023-05-09 | $2.35M derived: sum of 3 quarters · filed 2023-05-09 | $8.43M derived: sum of 4 quarters · filed 2023-05-09 | ||
| 2021-12-31 | $493.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $2.95M derived: sum of 2 quarters · filed 2023-02-23 | $9.03M derived: sum of 3 quarters · filed 2023-02-23 | $6.92M 10-K · filed 2023-02-23 | ||
| 2021-09-30 | $2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $8.53M derived: sum of 2 quarters · filed 2022-11-09 | $6.43M 10-Q · filed 2022-11-09 | $7.76M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $6.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $3.97M 10-Q · filed 2022-08-11 | $5.30M derived: sum of 3 quarters · filed 2022-08-11 | $5.93M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | -$2.10M 10-Q · filed 2022-05-12 | -$774.00K derived: sum of 2 quarters · filed 2022-05-12 | -$144.00K derived: sum of 3 quarters · filed 2022-05-12 | $1.43M derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $1.96M derived: sum of 2 quarters · filed 2022-03-15 | $3.53M derived: sum of 3 quarters · filed 2022-03-15 | $3.31M 10-K · filed 2022-03-15 | ||
| 2020-09-30 | $630.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $2.21M derived: sum of 2 quarters · filed 2021-11-09 | $1.99M 10-Q · filed 2021-11-09 | $3.09M derived: sum of 4 quarters · filed 2021-11-09 | ||
| 2020-06-30 | $1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $1.35M 10-Q · filed 2021-08-12 | $2.46M derived: sum of 3 quarters · filed 2021-08-12 | |||
| 2020-03-31 | -$221.00K 10-Q · filed 2021-05-10 | $886.00K derived: sum of 2 quarters · filed 2021-05-10 | ||||
| 2019-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $2.28M 10-K · filed 2021-03-16 | ||||
| 2019-09-30 | $1.17M 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |